Epperla, Narendranath
Zhao, Qiuhong
Chowdhury, Sayan Mullick
Shea, Lauren
Moyo, Tamara K.
Reddy, Nishitha
Sheets, Julia
Weiner, David M.
Geethakumari, Praveen Ramakrishnan
Kandarpa, Malathi
Bruno, Ximena Jordan
Thomas, Colin
Churnetski, Michael C.
Hsu, Andrew
Zurbriggen, Luke
Tan, Cherie
Lindsey, Kathryn
Maakaron, Joseph
Caimi, Paolo F.
Torka, Pallawi
Bello, Celeste
Ayyappan, Sabarish
Karmali, Reem
Kim, Seo-Hyun
Kress, Anna
Kothari, Shalin
Sawalha, Yazeed
Christian, Beth
David, Kevin A.
Greenwell, Irl Brian
Janakiram, Murali
Kenkre, Vaishalee P.
Olszewski, Adam J.
Cohen, Jonathon B.
Palmisiano, Neil
Umyarova, Elvira
Wilcox, Ryan A.
Awan, Farrukh T.
Alderuccio, Juan Pablo
Barta, Stefan K.
Grover, Natalie S.
Ghosh, Nilanjan
Bartlett, Nancy L.
Herrera, Alex F.
Shouse, Geoffrey
Article History
Received: 30 May 2022
Accepted: 8 July 2022
First Online: 16 July 2022
Declarations
:
: The study was approved by the institutional review boards at all the participating sites and performed in compliance with the Declaration of Helsinki.
: Not applicable.
: NE: Speakers Bureau for Incyte, Honoraria/consulting/ad boards for TG Therapeutics, Pharmacyclics, BeiGene, Seattle Genetics, and Novartis; Research funding BeiGene. TKM ad board for Seattle Genetics. NR: Consultancy KITE, AbbVie, BMS, Celgene; Research funding Genentech, BMS. PRG: Consultancy to Kite Pharma, Rafael Pharma, Pharmacyclics LLC, and BMS. PC: Research funding ADC Therapeutics, Genentech; Ad board: ADC Therapeutics, Genentech, Bayer, Verastem, KITE; Speakers Bureau Celgene. PT: Consulting fees from ADC Therapeutics, TG Therapeutics, Kura Oncology, and Genentech. SA: Consulting/Ad board for TG Therapeutics, Seattle Genetics, BeiGene, Intellisphere, Fate Therapeutics, AstraZeneca. RK: Advisory Board: Celgene Corporation, Gilead Sciences, Juno Therapeutics, Kite Pharma, Janssen, Karyopharm, Pharmacyclics, MorphoSys, Epizyme, Genentech/Roche, EUSA; Grants/Research Support: Celgene Corporation/Juno Therapeutics/BMS, Takeda, BeiGene, Gilead Sciences/Kite. Speakers Bureau: AstraZeneca, BeiGene, Gilead Sciences, MorphoSys. SK Consultation with Karyopharm and Incyte. YS: Research funding from BMS, Celgene, TG Therapeutics, and BeiGene and has consulted for TG Therapeutics and Epizyme. BC: Research funding: Acerta, Celgene, Genentech, Merch, Millennium, MorphoSys, Roche, Triphase; Ad board: Verastem, Seattle Genetics, AstraZeneca. MJ: Research funding Takeda, Fate, Nektar. AJO: Research funding Genentech, Spectrum Pharmaceuticals, TG Therapeutics, Adaptive Biotech. JCB: Consulting/Advisory board—Janssen, BeiGene, Astra Zeneca, Loxo/Lilly, Aptitude Health, Kite/Gilead, HutchMed; Research Funding: Astra Zeneca, BMS/Celgene, Genentech, Loxo/Lilly, Takeda, Novartis, HutchMed, BioInvent. NP: Research funding from Genentech and AbbVie. FTA: Consultancy to Genentech, AstraZeneca, AbbVie, Janssen, Pharmacyclics, Gilead Sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, BeiGene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme. JPA: Consulting fees and research funding from ADC Therapeutics. SKB: Consultancy Monsanto; Honoraria: Atara, Seattle Genetics, Janssen, Pfizer. NSG: Research funding Genentech; honoraria/consulting/ad boards Kite, ADC, Novartis. NG: Consulting/advisory role for Seattle Genetics, TG Therapeutics, AstraZeneca, Pharmacyclics, BMS, Gilead, BeiGene, Incyte, Karyopharm, Roche/Genentech, Novartis, Loxo/Lilly, Genmab, Adaptive Biotech. NLB: Research funding: ADC Therapeutics, Autolus, BMS, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Merck, Millennium, Pharmacyclics, Affirmed Therapeutics, Dynavax, Gilead, MedImmune, Novartis; Consulting/Ad board: Kite Pharma, Pfizer, ADC Therapeutics, Roche/Genentech, Seattle Genetics, BTG, Acerta. GS: Honoraria from Kite Pharmaceuticals and BeiGene. AFH: Consultancy: BMS, Merck, Gilead, Adaptive Biotech, Seattle Genetics, Karyopharm; Research funding: Merck, Genentech, Gilead, Seattle Genetics, Immune Design, AstraZeneca, Pharmacyclics, ADCT Therapeutics. QZ, SMC, LS, JS, DMW, MK, XJB, CT, MCC, AH, LZ, CT, KL, KM, CB, SHK, AK, KAD, IBG, VPK, EU, and RAW have no relevant COI.